BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

On March 24, 2020 BioInvent International AB ("BioInvent") (OMXS: BINV) reported an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre- and post-treatment with BI-1206 (Press release, BioInvent, MAR 24, 2020, View Source [SID1234555792]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SkylineDx is a molecular diagnostics company which focuses on the discovery of novel gene-based biomarkers with high clinical utility for patient targeting and stratification. Headquartered in Rotterdam, the Netherlands, SkylineDx operates a CAP/CLIA certified laboratory in San Diego, California, USA.

Together the companies will research and develop predictive immunological signatures to help identify patients with non-Hodgkin lymphoma (NHL) and solid cancers who are likely to show clinical responses if treated with BI-1206, BioInvent’s lead product candidate.

Martin Welschof, CEO of BioInvent, said: "We are delighted to be working with SkylineDx, a company that has built up a great deal of expertise in molecular diagnostics, which is essential for the development of targeted cancer therapies. Identifying the right patients who are likely to respond to treatment with BI-1206 will constitute a major asset in the development of this promising treatment and, along with FcγRIIB expression levels, should support the extension of its use to other malignancies."

Dharminder Chahal, CEO of SkylineDx, said: "It is a real pleasure to announce our collaboration with Bioinvent, a true pioneer in promising new cancer treatments. As a diagnostics company, we always strive for precision medicine. Joining forces to identify true responders in early phase pharmaceutical trials, will make mark an important milestone towards that goal."